Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, …

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. [2]

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

Jan 13, 2025 · Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Learn more …

Oct 31, 2024 · Explore Regeneron’s clinical pipeline. Our pipeline is powered by end-to-end research and development capabilities, and our portfolio of investigational medicines reflects …

Jan 13, 2025 · “Regeneron continues to diversify our commercial, clinical and research portfolios by relentlessly pushing the boundaries of innovation and technology,” said George D. …

Search for a Regeneron clinical trial based on condition, keyword, and location. Explore comprehensive information on our highlighted trials to learn more.

3 days ago · Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular …

19 hours ago · Regeneron announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License Application for linvoseltamab for the …